Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MNCs Eye Generics Buys To Enter Growing Southeast Asia Markets

This article was originally published in PharmAsia News

Executive Summary

Making generic pharmaceuticals have become a major tool for foreign drug makers to get access to emerging markets in Southeast Asia as those markets outstrip the developed world in growth rates. Many multinationals are seeing their chances of growth more limited in developed markets, so they look to generics as a way to diversify. Emerging markets are expected to grow three times as fast as Western markets, by 13 percent a year, and account for 40 percent of the global drug market by 2020. The proposed acquisition of India's Ranbaxy Laboratories by Japan's Daiichi-Sankyo is cited by analysts as indicative of interest in the developing world. (Click here for more
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069314

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel